Handk to introduce new anticancer drug
Published: 2009-11-26 06:58:00
Updated: 2009-11-26 06:58:00
Handok Pharm says it has recently signed a licensing agreement with the U.S. based Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, to develop and market Spectrum’s novel antineoplastic agent in Korea.
Apaziquone is a drug currently bei...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
